Mirum Pharmaceuticals' LIVMARLI Receives Reimbursement Recommendation By Canada's CADTH For Patients With Cholestatic Pruritus In Alagille Syndrome
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced that Canada's CADTH recommended public reimbursement for LIVMARLI for treating cholestatic pruritus in Alagille Syndrome patients. This follows Health Canada's authorization of LIVMARLI in 2023, marking it as the first and only approved medication for this condition in Canada. The recommendation is based on the ICONIC study's data, showing significant reductions in pruritus and serum bile acids. LIVMARLI is also approved in the U.S. and Europe for ALGS and PFIC.
April 02, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals' LIVMARLI receives a positive reimbursement recommendation from Canada's CADTH for treating cholestatic pruritus in Alagille Syndrome patients, following Health Canada's authorization.
The positive reimbursement recommendation from CADTH for LIVMARLI in Canada is a significant milestone for Mirum Pharmaceuticals. It not only enhances the drug's accessibility to patients in need but also potentially boosts the company's revenue in the Canadian market. Given that LIVMARLI is the first and only approved medication for cholestatic pruritus in Alagille Syndrome in Canada, this development could significantly impact Mirum Pharmaceuticals' market position and financial performance in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100